US Dollar vs MXN

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

XLO

Xilio Therapeutics (XLO)

Xilio Therapeutics Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XLO

1 2 3 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
06/05/2024	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:XLO	Xilio Therapeutics Inc
01/04/2024	15:05	GlobeNewswire Inc.	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:XLO	Xilio Therapeutics Inc
28/03/2024	06:05	GlobeNewswire Inc.	Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing	NASDAQ:XLO	Xilio Therapeutics Inc
28/03/2024	06:00	Business Wire	Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program	NASDAQ:XLO	Xilio Therapeutics Inc
28/02/2024	15:01	GlobeNewswire Inc.	Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference	NASDAQ:XLO	Xilio Therapeutics Inc
31/01/2024	15:01	GlobeNewswire Inc.	Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference	NASDAQ:XLO	Xilio Therapeutics Inc
19/01/2024	15:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XLO	Xilio Therapeutics Inc
08/01/2024	06:30	GlobeNewswire Inc.	Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies	NASDAQ:XLO	Xilio Therapeutics Inc
03/01/2024	15:38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
07/12/2023	06:30	GlobeNewswire Inc.	Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data	NASDAQ:XLO	Xilio Therapeutics Inc
09/11/2023	15:17	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XLO	Xilio Therapeutics Inc
09/11/2023	15:10	Edgar (US Regulatory)	Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]	NASDAQ:XLO	Xilio Therapeutics Inc
09/11/2023	15:05	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:XLO	Xilio Therapeutics Inc
09/11/2023	15:01	GlobeNewswire Inc.	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results	NASDAQ:XLO	Xilio Therapeutics Inc
03/11/2023	11:00	GlobeNewswire Inc.	Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors	NASDAQ:XLO	Xilio Therapeutics Inc
31/10/2023	08:15	GlobeNewswire Inc.	Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting	NASDAQ:XLO	Xilio Therapeutics Inc
27/09/2023	16:02	GlobeNewswire Inc.	Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	NASDAQ:XLO	Xilio Therapeutics Inc
07/09/2023	15:23	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
05/09/2023	07:30	GlobeNewswire Inc.	Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer	NASDAQ:XLO	Xilio Therapeutics Inc
05/09/2023	06:30	GlobeNewswire Inc.	Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference	NASDAQ:XLO	Xilio Therapeutics Inc
14/08/2023	06:30	GlobeNewswire Inc.	Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results	NASDAQ:XLO	Xilio Therapeutics Inc
03/08/2023	15:05	GlobeNewswire Inc.	Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer	NASDAQ:XLO	Xilio Therapeutics Inc
13/06/2023	15:31	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XLO	Xilio Therapeutics Inc
13/06/2023	15:06	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XLO	Xilio Therapeutics Inc
25/05/2023	16:01	GlobeNewswire Inc.	Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors	NASDAQ:XLO	Xilio Therapeutics Inc
09/05/2023	06:51	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:XLO	Xilio Therapeutics Inc
09/05/2023	06:30	GlobeNewswire Inc.	Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results	NASDAQ:XLO	Xilio Therapeutics Inc
25/04/2023	15:11	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:XLO	Xilio Therapeutics Inc
25/04/2023	15:06	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:XLO	Xilio Therapeutics Inc
10/04/2023	15:58	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:XLO	Xilio Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:XLO

1 2 3 Próxima >

Verizon Communications

Health Care Select Sector

Euro vs US Dollar

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones